Developmental Funds: CCSG Developmental Funds are critical for realizing the Research Strategic Plan (RSP). These investments support RSP elements emphasizing integrative science, innovation, and collaboration. In the previous renewal, MCC requested and was recommended to receive $400,000 per year in Developmental Funds for pilot projects and shared resources. However, after administrative reductions only $75,000 in CCSG developmental funding was available over the five-year period. These funds were leveraged with significant institutional funds to support pilot projects, which was ultimately the only category for which CCSG Developmental Funds were used. This CCSG investment returned more than $20 million in subsequent peer-reviewed funding and 54 publications. Future plans are to support collaborative pilot projects and invest in a novel mechanism to foster innovation in MCC cores over the next project period. MCC requests $190,000 for Developmental Funds to: 1) Foster innovative science through the support of collaborative pilot projects; and 2) Facilitate and Encourage Core Innovation. MCC will continue to recruit new faculty, allocate discretionary ?pre- pilot? funds for Program Leaders, and provide bridge funding for members; however this will be institutional support, and no CCSG funding is requested in these categories at this time. Staff Investigators: MCC's Centers of Excellence (CoE) build and foster transdisciplinary collaborations across all Research Programs based on areas of institutional strength that align with the needs of the catchment area. Staff Investigators lead each CoE, with the expectation that they bring together members from across all Research Programs to enhance discovery and translation through interdisciplinary and transdisciplinary team science. MCC has four CoEs, each led by a Staff Investigator, who reports directly to the Associate Center Director (ACD) of Translational Science. The four Staff Investigators, all of whom are accomplished, senior scientists, are: 1) Kieran Smalley, PhD, who leads the Melanoma CoE; 2) Eric Haura, MD, who leads the Lung Cancer CoE; 3) Anna Giuliano, PhD, who leads the Center for Infection Research in Cancer; and 4) Robert Gillies, PhD, who leads the Center for Imaging and Technology. MCC requests Staff Investigator support of 1.20 calendar months (10%) for the CoE Directors, partially supported by the CCSG ($44,725).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-20
Application #
9419791
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Poort, Hanneke; Meade, Cathy D; Knoop, Hans et al. (2018) Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs 41:E28-E37
Pamnani, Shitaldas J; Sudenga, Staci L; Rollison, Dana E et al. (2018) Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis 218:1219-1227
Dai, Juncheng; Li, Zhihua; Amos, Christopher I et al. (2018) Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis :
Cherezov, Dmitry; Hawkins, Samuel H; Goldgof, Dmitry B et al. (2018) Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial. Cancer Med 7:6340-6356

Showing the most recent 10 out of 1254 publications